[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-organ-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-organ-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,77,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639232","adding-a-gastrointestinal-subscore-to-sofa2-for-mortality-risk-assessment-in-the-icu-the-sofa2-gis-study-100639232",false,"NCT07586254","Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in the ICU: The SOFA2-GIS Study","Development and Validation of the SOFA2-GIS Score: Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in Critically Ill Patients - A Multicenter Prospective Observational Cohort Study","SOFA2-GIS","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Admission to a participating intensive care unit\n* Expected ICU length of stay of at least 24 hours\n* Availability of clinical and laboratory data required to calculate the SOFA2 score and the AGI grade within the first 24 hours of ICU admission\n* Written informed consent obtained from the patient or, when not feasible due to the patient's clinical condition, from a legally authorized representative\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pregnancy\n* ICU length of stay shorter than 24 hours (including patients who die or are discharged within the first 24 hours)\n* ICU readmission during the same hospital stay (only the index admission will be included)\n* Postoperative admission for routine monitoring without organ dysfunction (planned short-term observation following elective surgery)\n* Admission solely for end-of-life care or with treatment limitations (do-not-resuscitate or withdrawal of life-sustaining therapy decisions) made within the first 24 hours of admission\n* Patients with primary gastrointestinal pathology as the reason for ICU admission that would confound AGI grading (e.g., gastrointestinal surgery within the preceding 7 days, acute mesenteric ischemia as the primary diagnosis)\n* Patients with anatomical or functional conditions precluding standard AGI assessment (e.g., short bowel syndrome, permanent gastrostomy\u002Fjejunostomy with chronic feeding intolerance, chronic intestinal pseudo-obstruction)\n* Refusal of consent by the patient or legal representative\n* Participation in an interventional clinical trial that may affect outcome measures","ALL","18 Years",{"count":20,"type":21},800,"ESTIMATED","3 Months","OBSERVATIONAL","The goal of this observational study is to learn whether adding a gastrointestinal (GI) component to a widely used organ failure score improves the prediction of death risk in critically ill adults treated in the intensive care unit (ICU).\n\nThe Sequential Organ Failure Assessment 2 (SOFA2) score is used in ICUs to measure how severely a patient's organs are failing. The current version evaluates six organ systems but does not include the gastrointestinal system, even though gut dysfunction is common and serious in critically ill patients. Researchers in this study will add a GI subscore based on the European Society of Intensive Care Medicine (ESICM) Acute Gastrointestinal Injury (AGI) classification and create a new combined score called SOFA2-GIS.\n\nThe main questions this study aims to answer are:\n\nDoes adding a gastrointestinal subscore to the SOFA2 score improve the prediction of 28-day mortality in ICU patients? Does the new SOFA2-GIS score perform better than the standard SOFA2 score in identifying patients at higher risk of dying in the ICU or in the hospital?\n\nResearchers will compare the standard SOFA2 score with the new SOFA2-GIS score in the same patients to see which one better predicts patient outcomes.\n\nParticipants will:\n\nReceive their usual ICU care without any change, additional treatment, or extra tests Be evaluated using routinely collected clinical and laboratory information during the first 24 hours of ICU admission Be followed during their hospital stay to record outcomes such as length of stay, need for mechanical ventilation, need for dialysis, and survival\n\nThis is a multicenter, prospective, observational cohort study conducted in tertiary ICUs in Türkiye. No additional procedures, tests, or interventions will be performed for the purpose of this study.",[26,27,28,29],"Critical Illness","Multiple Organ Failure","Gastrointestinal Diseases","Mortality",[31,32,33,15,34,35,36],"sofa2","sofa-2","Sequential Organ Failure Assessment","Organ dysfunction score","Prognostic score","ICU mortality","NOT_YET_RECRUITING","2026-05-20",{"date":40,"type":41},"2026-05-26","ACTUAL",{"date":43,"type":21},"2026-07",{"date":45,"type":21},"2027-03",{"name":47,"class":48},"Ozkul Yilmaz Colak","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100384663","impact-of-metabolite-supplementation-to-restore-mitochondrial-dysfunction-during-septic-shock-a-preclinical-study-100384663","NCT04288635","Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study","Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study: MEFDASE Study","MEFDASE","Inclusion Criteria:\n\n* All patients aged 18 or more\n* Patients with criteria for septic shock according to SEPSIS 3 definition (presumed sepsis, with persisting hypotension requiring vasopressors to maintain mean arterial pressure \\> 65 mmHg and having a serum lactate \\> 2 mmol\u002FL despite adequate fluid expansion).\n* Admitted in the ICU of Angers University Hospital\n\nExclusion Criteria:\n\n* Minor patients (aged less 18)\n* Patient subject to legal protection measures\n* Refusal of the patient or his family\n* Preexisting mitochondrial disease\n* Patient with aplasia\n* Pregnant or parturient women",{"count":59,"type":21},55,"28 Days","Septic shock is defined as a subset of sepsis with severe metabolism alterations, leading to organ failure. Septic shock is associated with a high mortality, around 40% according to the SEPSIS 3 definition.\n\nMetabolic alterations are responsible for lactic acidosis, and results in mitochondrial dysfunction.\n\nThis study aims at evaluate the impact of exogenous metabolites on restoring mitochondrial function in septic shock patients with lactate acidosis.\n\nMitochondrial metabolism (quantitative analysis, mitochondrial function) in intact Peripheral Blood Mononuclear Cells (PBMC) will be isolate and analyse from patients at the early phase of septic shock (admission), at day 2 and 4. Participant's medical history will be recorded: renal and liver metabolism, severity scores and outcomes and the need for supportive care in the intensive care unit (ICU) until 28 days after admission.\n\nFurthermore, the investigators will evaluate wether selected metabolites added to the cell culture medium may improve mitochondrial metabolism.",[63,27],"Septic Shock",[65],"mitochondrial dysfunction","RECRUITING","2025-12-02",{"date":69,"type":41},"2025-12-08",{"date":71,"type":41},"2020-07-09",{"date":73,"type":21},"2026-08-09",{"name":75,"class":76},"University Hospital, Angers","OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100369752","burden-mortality-and-supply-costs-in-intensive-care-unit-patients-100369752","NCT04094428","Burden, Mortality and Supply Costs in Intensive Care Unit Patients","Burden, Mortality and Supply Costs in Intensive Care Unit Patients. Health Services Research.","PLV_Ulm","Inclusion Criteria:\n\n* All patients dying on the ICU and all patients staying for at least 72 hours on the ICU\n\nExclusion Criteria:\n\n* No",{"count":86,"type":21},700,"This study systematically observes in a pragmatic trail under real world conditions the association between strategies of therapy (maximal therapy, withhold, withdraw) and treatment success in three endpoint related initial risk groups (high, intermediate, low risk) regarding three endpoints (burden, mortality and supply costs).",[89,29,90,91,92,93,27],"Burden, Dependency","End-of-life Care","Intensive Care Unit","Critically Ill Patient","Frailty",[95,96,97,98,99,100,27],"burden","mortality","end-of-life care","intensive care unit","critically ill patient","frailty","2024-01-16",{"date":103,"type":41},"2024-01-17",{"date":105,"type":41},"2019-10-21",{"date":107,"type":21},"2026-09-30",{"name":109,"class":48},"University of Ulm",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100389854","exosome-of-mesenchymal-stem-cells-for-multiple-organ-dysfuntion-syndrome-after-surgical-repaire-of-acute-type-a-aortic-dissection-100389854","NCT04356300","Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection","Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection: a Pilot Study","Inclusion Criteria:\n\n* Part 1:\n\n  * Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft\n  * elder than 60 years old\n  * Preoperative PaO2\u002FFiO2 ≥ 400mmHg, platelets ≥ 150\\*109\u002FL, bilirubin≥ 20μmol\u002FL, no hypotension (without vasoactive drugs), Glasgow Coma Score Scale = 15, creatine ≥110μmol\u002FL\n\nPart 2:\n\n* Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft\n* Patients who have failure of at least 2 organs\n* Patients who meet the criteria as below:\n\nsequential organ failure assessment score (SOFA) ≥ 10\n\nExclusion Criteria:\n\n* • uncontrollable underlying disease life expectancy of less than 4 days history of long-term corticosteroid use during the past 6 months.\n\n  * The pre-operative computer tomography angiography(CTA) demonstrate the visceral arteries are involved\n  * pre-existing severe disease of any major organs","20 Years","80 Years",{"count":120,"type":21},60,"INTERVENTIONAL",[123],"NA","Multiple organ dysfunction syndrome (MODS) after surgical repaired for acute type A aortic dissection (ATAAD) is a life-threatening condition. In this study, patients who undergoing surgical repaired of ATAAD immediately or presenting sever MODS after surgical repaired of acute type A aortic dissection will be treated with umbilical cord-derived mesenchymal stem cell.",[27],"2020-05-05",{"date":128,"type":41},"2020-05-06",{"date":130,"type":21},"2020-09-01",{"date":132,"type":21},"2030-09-01",{"name":134,"class":48},"Fujian Medical University"]